Member Info for Tommy85

great post iron, love you have stuck to facts rather than the deramping narrative that porky and his merry men have come in with. all we need is cobalt and then we have a full house of ****s

fact is, when trx and euda merge, link to the merge here https://www.globenewswire.com/news-release/2023/10/05/2755433/0/en/euda-health-holdings-limited-enters-into-letter-of-intent-for-proposed-merger-with-theoremrx-inc.html will be transformational for valirx. thx deal $61mn with royalties, inflection point bonuses, monthly service agreement, $2.2mn upfront and $37mn per other indications added. loi for exclusivity of proper merger between euda and trx october 4th, november 4th when the 30 day exclusivity period ends, not long now, or maybe enough dd has been done it will get over the line quicker?

this will drag the mcap up from the ridiculous low level it is at present! and a bit of optimism here, when 201 is done, think about the amount of doors it will open? trx fancy first dibs on 301,401 or the current novel clx tnbc?

see the amount of green ribbons for filtered posters is multiplying currently, they on triple rate for weekends?

Clarence dear boy, how art thou? Filtered that chap that shall not be named ages ago. One minute he / she was ramping, next de ramping, very bizarre, obvious agenda there. Think most investors who look at a share do their own research anyway. After so long seems to be some positive news to look forward to, TRx/ euda merge, 30 days as of 4th October, to finalise negotiations, maybe all the dd done before hand could settle before then? US $2.2 mill = current exchange rate £1.8 mill, then as quoted from the RNS Signs Letter of Intent to Sub-License VAL201, 02/11/21 ‘Subject to successful market authorisation, the potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx’ Would also love to see what ‘Cathy is cooking’ with all these 3/4 again quoted from a recent rns ‘With an ambition to secure 3-4 new evaluation projects every year, we have been focussing substantial effort on identifying and qualifying further assets that meet our criteria to build a diversified preclinical project pipeline’ would certainly set the cat amongst said pigeons!

Great to have you back TDK! Want to see Cathys SPVs she has actively been working on to fulfill these 4 per year, 4 in 6 months? Come on cathy, the floor is yours :)

Good post Wallcrawler, point 3. Invite Hargreaves onto the board is a no brainer, the mans a genius and will help increase the SP, win win. Come on Suze, take note of this massive opportunity . P.S this is of course if he wants this responsibility :)

Thats why i was trying to match Dr Catherine ("Cathy") Tralau-Stewart previous global alliance director with Takeda yesterday HD

Or 301 with the Takeda relationship RB :)

Great appointment, still sure Takeda are the little sods with 301, with Dr Catherine ("Cathy") Tralau-Stewart links with previous director alliances with Takeda, could be a perfect appointment :)

TDK, get back in the telegram group :)

CB watching your very limited and change in slant of discussion is comical to see. Hope you find your 6p entry with Sporky and the rest of the goblins that have surfaced all of a sudden. ATB :)

Mer, I have been here for a long time and can remember when you used to be positive around Valirx. Understand you may have been burnt previously, like us all, but i like the risk vs reward ratio Valirx currently resides in. After Adams excellent post, probably the most recommended post on this BB in all honesty, we see ourselves trying to get the best out of the current situation. I, like many are down on my investment currently, but with optimism see a good plan ahead. We just need this long overdue 201 TRx news and will be seen in a different light. Totally different strategy to that of the gruesome twosome mentioned FYI. ATB whatever your current investment strategy is.

Nom, never really understood your position here to be honest, but in that post aren’t you focusing on macro economic events which have nothing to do with Val?

Good to see you back posting Freddie :) is Valju still around / invested?

I agree with OB here porky, good set of extensive questions being posed. Watch out for the brigade of unsettled posters this week, actually think they have arrived already, obviously have ulterior motives and you can see right through them! All eyes on VAL this week, come on suze let’s get some news out that we have been waiting for. ATB :)

Merry Christmas fellow Valerites, cracking year and still not over yet. Already excited for 2022 :)

Lovely news OB good to have you on the BB as always, keeping some moderation may I say.

One of mine also, proper kernow boy

4.72 good target, will hold until then and then retire :)

OB, was sad to hear this news today, a legend! Also, what happened to your 4.50 target? Or something around that mark :)

Excellent TH, favorite piece in the Q+A, and what any private investor would like to hear before investing in a company. Great work Suzy and team.

We are currently working with Cenkos to build a following of interested Institutional Investors. We do
not currently intend to place new shares in an equity placing for the purposes of raising working capital,
or for the purposes of letting Institutional Investors onto the shareholder register.

Whilst on the US piece, would be good to know if the office in Boston is still operational https://www.investegate.co.uk/valirx-plc/rns/valirx-establishes-us-office-in-boston--ma/201511050700066237E/

Such a comprehensive podcast earlier, absolutely brilliant! The so went up after the q+a a few weeks back, after the podcast today I can see it going mad, 8am auction comes to mind :) Well done Suzy and team :)

Great posts Porko, gives a great synopsis of where Val are now. Totally different breed, looking forward to hearing suze tomorrow and then Monday morning action :) remember how mad it went after the last q+a interview

Whats L2 looking like RB, havent had that for a while

Thanks Adam, very interesting. I see that Astellas in partnership with Medivaiton sold Xtandi to Pfizer for $14 billion. I am by no means qualified to discuss figures and please correct me if i'm wrong, but from research Xtandi ORR of 50% and VAL-201 ORR of 54%, no brainier isn't it? :) Then begs the question, is it Astellas the Japanese pharma currently reviewing 301? You can have 201 + 301 for $20 billion, put me in control of sales + marketing for Val hahaha